File No. 12-67/2017-DC (Pt-Alkem-SND)
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(Subsequent New Drugs Division)

Dated 31 OCT 2019

To,

M/s. Alkem Laboratories Ltd.,
'Alkem House', Senapati Bapat Road,
Lower Parel (W), Mumbai – 400013.

Subject: Permission for conducting Phase-III clinical trial "A Randomized Double Blind, Multicentric, Parallel-group, Phase III Clinical Trial to evaluate the Efficacy & Safety of 5% Spironolactone Topical Cream versus Placebo in patients with Acne Vulgaris" - regarding.

CT NOC No. CT/SND/98/2019

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigator and as per the **Protocol No: ALK20-SP12, Phase III, and Version 2.0, Dated 16-07-2019** submitted to this Directorate.

S.No	Investigator and Trial site	Ethics Committee Name and Registration Number
1	Dr. Davinder Prasad., Department of Dermatology, PGIMER, Chandigarh.	Institutional Ethics Committee, Post Graduate Institute of Medical Education and Research, Room No. 6006, Sixth Floor, PN Chuttani Block, Chandigarh-160012. ECR/25/Inst/ch-2013-RR-16
2	Dr. Jayesh Mukhi, Government Medical college & Hospital Department of Skin, VD & Leprology, Government Medical college & Hopital, Medical square-440003, Nagpur, Maharashtra.	Institutional Ethics Committee, Department of Pharmacology, Govt. Medical College, Nagpur. ECR/43/Inst/MH/2013

3	Dr. Gautam Banerjee., Culcutta School of Tropical Medicine, 108, Chittaranjan Ave,Calcutta Medical College, College Squre, Kolkata, West Bengal – 700073.	Institutional Ethics Committee, Medical college Kolkatta – 73. ECR/194/Inst/WB/2013/RR-16
4	Dr. Vijay Palwal, SMS Medical College and Hospital, Department-Surgery, SMS Medical College & Attached Hospital's J.L.N. Marg, Jaipur- 302001, Rajashan.	Office of the ethics committee, SMS Medical College & Attached Hospital's J.L.N. Marg, Jaipur- 302001, ECR/26/Inst/Raj/2013/RR-16
5	Dr. Pramod Kumar, Kasturba Medical College, Attavar, Mangalore.	Institutional Ethics Committee, Kasturba Medical College, Attavar, Mangalore. ECR/191/Inst/KL/2013/RR-16
6	Dr. Bikas Ranjan Kar, IMS and SUM Hopital, Bhuvaneshwar.	Ethics Committee, IMS R SUM Hospital Bhuvaneshwar. ECR/627/Inst/OR/2014/RR-17
7	Dr. B.L. Nanjundaswamy, Mysore Medical College, Professor & HOD, Dept. of Skin and S.T.D.K.R. Hospital, Mysore Medical College & RI, Mysore-	Ethics Committee, Mysore Medical College and research Institute, Irwin Road, Mysore – 570001. ECR/134/KA/Inst/2013/RR-16
8	Dr. Manjunath Shenoy, Yenepoya Medical College, University Road, Deralakatte, Mangalore- 575018.	Yenepoya Ethics Committee, Medical College, University Road, Deralakatte, Mangalore- 575018. ECR/521/Inst/KA/2013/RR-16
9	Dr. Karina Patel GMERS Medical college and civil Hospital, sola, Ahmedabad	Institutional Ethics Committee, GMERS Medical College, Sola, S.G. Highway, Near New Gujarat High Court, Ahmedabad-380061, Gujarat ECR/404/Inst/GJ/2013/RR-16

10	Dr. Teja Kulkarni, Chopda Medicare and Research Centre Pvt Magnum heart Institute, plot no. 3/5, Laxmi Nagar, Patil Lane No.-1, Near K.B. H. Vidyalaya, Opp, Vasant Market, Canada Corner Nashik Maharashtra.	Megna care Ethics Committee Chopda Medicare and Research Centre Pvt Magnum heart Institute, plot no. 3/5, Laxmi Nagar, Patil Lane No.-1, Near K.B. H. Vidyalaya, Opp, Vasant Market, Canada Corner Nashik Maharashtra. ECR/79/Inst/MH/2013/RR-16
11	Dr. Rachita Dhurat Lokmanya Tilak Municipal medical College, Department of Dermatology, Sion, Mumbai-400022.	Institutional Ethics Committee Lokmanya Tilak Municipal medical College, Departmnt of Dermatology, Sion, Mumbai-400022 ECR/266/Inst/MH/2013/RR-2016
12	Dr. Usha Khemani Gokuldas Tejpal Hospital, Department of Dermatology, Grant Government Medical College and J J Group of Hospital, Near Police Commissioners Office, Lokmanya Tilak marg, fort, GPO Mumbai-400001, Maharashtra.	Department of Pharmacology, Grant Government Medical College and J J Group of Hospital, Byculla, Mumbai-400001, Maharashtra. ECR/382/Inst/MH/2013/RR-2016
13	Dr. Sonal Shendkar Lifepoint Multispeciality Hospital 145/1, Mumbai-Banglore highway Near Hotel Sayaji Wakad Pune 411057.	LPR ethics committee Lifepoint Mutispeciality Hospital 145/1, Mumbai-Banglore highway Near Hotel Sayaji Wakad Pune 411057 ECR/751/Inst/Maha/2015/RR-18
14	Dr. Sharmila Patil Dr. D Y Patil Hospital and Research Centre, OPD 54 1st floor, Sec 5, Nerul Navi Mumbai 4000706 Maharashtra	Dr. D Y Patil Hospital and Research Centre, OPD 54 1st floor, Sec 5, Nerul Navi Mumbai 4000706 Maharashtra ECR/195/Inst/MH/2013/RR-16
15	Dr. Sharad Mutalik Maharashtra Medical Foundation Josho Hospital, 778, Shivaji nagar Opp Kamala Nehru park Pune-411004.	Institutional Ethics Committee Maharashtra Medical Foundation Josho Hospital, 778, Shivaji nagar Opp Kamala Nehru park Pune-411004. ECR/311/Inst/MH/2013/RR-16
16	Dr.Ashish Ramchandrarao Deshmukh MGM Medical College N-6 CIDCO Aurangabad-431003 Maharashtra India .	MGM Ethics Committee for Research on Human Subjects at Pharmacology Department MGM Medical College N-6 CIDCO Aurangabad-431003 Maharashtra India ECR/581/Inst/MH/2014/RR-17

17	Dr. Smita Nagpal, Saviour Hospital Near Bharat Petrol Pump Lakhudi Talav Stadium Road navrangpur Ahmedabad-380014 Gujarat.	Saviour Hospital Ethics Committee, Near Bharat Petrol Pump Lakhudi Talav Stadium Road navrangpur Ahmedabad-380014, Gujarat. ECR/656/Inst/GJ/2014/RR-17
18	Dr. Ruchir Shah, Sanjivani Super Speciality Hospital Pvt. Ltd., Ahmedabad-380 015.	Sanjivani Hospital Ethics Committee 1, New Uday Park Soc., Nr. Sunrise Park, Vastrapur, Ahmedabad-380 015. ECR/183/Inst/AH/2013-RR-16
19	Dr.Rashmi Sungh, Sudbhawana Hospital , B-31/80, 23-B, Bhogabir Lanka Varanasi Uttar Pradesh.	Ethics Committee Sudbhawana Hospital , B-31/80, 23-B, Bhogabir Lanka Varanasi Uttar Pradesh. ECR/667/Inst/UP/2014/RR-17.
20	Dr. Satyendra Kumar Singh, Institute of medical Sciences, Department of Dermatology and Venereology, Banaras Hindu University Varanasi UP.	Ethics Committee Institute of medical Sciences Banaras Hindu University Varanasi UP. ECR/526/Inst/ UP/2014/RR-17
21	Dr. Prashant Keshavrao Palwade Ishwar Institute of health Care, iswar hights, Plot No. 7, Gut No. 6/1, Beside Panjabi Bhavan Jaysingpura Aurangabad Maharashtra India.	Ethics Committee Ishwar Institute of health Care, iswar hights, Plot No. 7, Gut No. 6/1, Beside Panjabi Bhavan Jaysingpura Aurangabad Maharashtra India. ECR/988/Inst/MH/2017
22	Dr. Shatrughan Sahay, Ajanta Research Centre Ajanta Hospital and IVF Center 765 ABC Complex Kanpur Road Alambagh Lucknow 226005 UP India.	Institutional Ethics Committee Ajanta Research Centre Ajanta Hospital and IVF Center 765 ABC Complex Kanpur Road Alambagh Lucknow 226005 UP India. ECR/611/Inst/UP/2014/RR-17
23	Dr. Pradhan Shekhar, Nana BJ Govt Medical College and Sassoon General Hospital Dept of Skin and VD, Pune Railway Station Road, Pune-411001.	Institutional Ethics Committee BJ Govt Medical College and Sassoon General Hospital, Dept of Pharmacology, Pune Railway Station Road, Pune-411001. ECR/280/Inst/Maha/2013/RR-16
24	Dr. Vaibhav Kalambe, AIMS Hospital, P-72, Milap Nagar MIDC Dombivli (E) 421203.	Suraksha Ethics Committee AIMS Hospital, P-72, Milap Nagar MIDC Dombivli (E) 421203. ECR/644/Inst/MH/2014/RR-17

Kindly note that this permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940:

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the

Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from

the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

Yours faithfully,

(Dr. V. G. Somani)
Drugs Controller General (India)
(Name & Designation of Licensing Authority)